Otsuka (OTCMKTS:OTSKY) Trading 9.1% Higher – Still a Buy?

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY)’s stock price shot up 9.1% on Monday . The company traded as high as $35.94 and last traded at $35.94. Approximately 758 shares changed hands during trading, a decline of 98% from the average session volume of 40,074 shares. The stock had previously closed at $32.94.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded shares of Otsuka from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 31st. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

Otsuka Stock Down 0.1%

The stock has a market capitalization of $38.74 billion and a P/E ratio of 15.22. The company’s 50-day moving average price is $34.56 and its 200 day moving average price is $32.79. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.67 and a current ratio of 2.17.

Otsuka (OTCMKTS:OTSKY) last released its earnings results on Tuesday, April 28th. The company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.16. The firm had revenue of $3.96 billion during the quarter, compared to analysts’ expectations of $3.78 billion. Otsuka had a return on equity of 12.33% and a net margin of 15.01%.Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. As a group, equities analysts expect that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 1.98 earnings per share for the current year.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.